Industry leaders join together for historic Accelerating Cancer Cures Research Symposium

March 6th, 2012
Today, the Damon Runyon Cancer Research Foundation held its first Accelerating Cancer Cures Research Symposium, focused on rebuilding the ranks of physician-scientists specially trained to translate laboratory discoveries into new cancer therapies. The event, held at Pfizer Inc headquarters, brought together academic scientists and other leading pharmaceutical companies, including Eli Lilly and Company, Celgene, Genentech, Merck, and Millennium: The Takeda Oncology Company.

The symposium is the first of its kind since Damon Runyon, a New York-based foundation, launched its Accelerating Cancer Cures program in June 2011. Accelerating Cancer Cures is a five-year, multi-million dollar project that will train a new generation of exceptional clinical investigators capable of translating the latest scientific discoveries into new diagnostics and therapeutics for cancer patients. The initiative also eliminates barriers to progress by fostering communication and collaboration between academia and industry. It is supported by some of the world's leading companies and The Pharmaceutical Research and Manufacturers of America (PhRMA).

"We risk losing tremendous ground in our effort to find cures for cancer if we cannot attract new talent and new ideas to clinical research," said Damon Runyon Cancer Research Foundation President and CEO Lorraine Egan when the program launched. "Our best hope for crucial breakthroughs to prevent, diagnose and treat cancer lies with the committed young scientists who will be able to pursue critical translational research thanks to this effort."

Scientists from the nation's leading research institutions, including the Dana-Farber Cancer Institute, Fred Hutchinson Cancer Research Center, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, and the University of North Carolina, Chapel Hill, traveled to New York to attend.

Pfizer Vice President Jamey R. Skillings, MD, MSc, MBA, led a discussion on targeted therapies for cancer, and Celgene Vice President Rajesh Chopra, MD, PhD, chaired a session on immunotherapies. They were joined by twenty Damon Runyon-funded scientists.

The day ended with a panel discussion, moderated by Damon Runyon Chief Scientific Officer Yung S. Lie, PhD, about navigating the boundaries between industry and academia and overcoming barriers to collaboration and translational research.

More information:
http://www.damonrunyon.org/accelerate

Provided by Damon Runyon Cancer Research Foundation

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Netherlands bank customers can get vocal on payments

Are some people fed up with remembering and using passwords and PINs to make it though the day? Those who have had enough would prefer to do without them. For mobile tasks that involve banking, though, it is obvious that ...

How bees naturally vaccinate their babies

When it comes to vaccinating their babies, bees don't have a choice—they naturally immunize their offspring against specific diseases found in their environments. And now for the first time, scientists have discovered how ...

Earth flyby of 'space peanut' captured in new video

NASA scientists have used two giant, Earth-based radio telescopes to bounce radar signals off a passing asteroid and produce images of the peanut-shaped body as it approached close to Earth this past weekend.

Image: Hubble sees a dying star's final moments

A dying star's final moments are captured in this image from the NASA/ESA Hubble Space Telescope. The death throes of this star may only last mere moments on a cosmological timescale, but this star's demise is still quite ...

Exoplanets 20/20: Looking back to the future

Geoff Marcy remembers the hair standing up on the back of his neck. Paul Butler remembers being dead tired. The two men had just made history: the first confirmation of a planet orbiting another star.

New blow for 'supersymmetry' physics theory

In a new blow for the futuristic "supersymmetry" theory of the universe's basic anatomy, experts reported fresh evidence Monday of subatomic activity consistent with the mainstream Standard Model of particle physics.

A cataclysmic event of a certain age

At the end of the Pleistocene period, approximately 12,800 years ago—give or take a few centuries—a cosmic impact triggered an abrupt cooling episode that earth scientists refer to as the Younger Dryas.